181 related articles for article (PubMed ID: 30767625)
1. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
Nath V; Agrawal R; Kumar V
J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
[TBL] [Abstract][Full Text] [Related]
2. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel G-protein-coupled receptor 40 (GPR40) agonists by hybrid
Nath V; Ahuja R; Kumar V
J Biomol Struct Dyn; 2019 Sep; 37(14):3764-3787. PubMed ID: 30252605
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations.
Liu X; Jing Z; Jia WQ; Wang SQ; Ma Y; Xu WR; Liu JW; Cheng XC
J Biomol Struct Dyn; 2018 Aug; 36(11):2988-3002. PubMed ID: 28853334
[TBL] [Abstract][Full Text] [Related]
5. Virtual identification of novel PPARα/γ dual agonists by 3D-QSAR, molecule docking and molecular dynamics studies.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
J Biomol Struct Dyn; 2020 Jun; 38(9):2672-2685. PubMed ID: 31418313
[TBL] [Abstract][Full Text] [Related]
6. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.
Chen KC; Chang SS; Huang HJ; Lin TL; Wu YJ; Chen CY
J Biomol Struct Dyn; 2012; 30(6):662-83. PubMed ID: 22731403
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.
D'Aniello E; Fellous T; Iannotti FA; Gentile A; Allarà M; Balestrieri F; Gray R; Amodeo P; Vitale RM; Di Marzo V
Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):586-597. PubMed ID: 30611848
[TBL] [Abstract][Full Text] [Related]
8. Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.
Liu L; Ma Y; Wang RL; Xu WR; Wang SQ; Chou KC
Drug Des Devel Ther; 2013; 7():279-88. PubMed ID: 23630413
[TBL] [Abstract][Full Text] [Related]
9. Scaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptors.
Zhang LS; Wang SQ; Xu WR; Wang RL; Wang JF
PLoS One; 2012; 7(10):e48453. PubMed ID: 23119024
[TBL] [Abstract][Full Text] [Related]
10. Structure-based virtual screening and discovery of New PPARδ/γ dual agonist and PPARδ and γ agonists.
Maltarollo VG; Togashi M; Nascimento AS; Honorio KM
PLoS One; 2015; 10(3):e0118790. PubMed ID: 25767888
[TBL] [Abstract][Full Text] [Related]
11. Exploring Dual Agonists for PPARα/γ Receptors using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.
Ding TT; Liu YY; Zhang LM; Shi JR; Xu WR; Li SY; Cheng XC
Comb Chem High Throughput Screen; 2022; 25(9):1450-1461. PubMed ID: 34182904
[TBL] [Abstract][Full Text] [Related]
12. Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives.
Lather V; Kairys V; Fernandes MX
Chem Biol Drug Des; 2009 Apr; 73(4):428-41. PubMed ID: 19243388
[TBL] [Abstract][Full Text] [Related]
13.
Feng XY; Ding TT; Liu YY; Xu WR; Cheng XC
J Biomol Struct Dyn; 2021 Mar; 39(5):1853-1864. PubMed ID: 32189570
[TBL] [Abstract][Full Text] [Related]
14. Identification of Potential PPAR γ Agonists as Hypoglycemic Agents: Molecular Docking Approach.
Mishra GP; Sharma R
Interdiscip Sci; 2016 Sep; 8(3):220-8. PubMed ID: 26374652
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation and structural insights for design of subtype-selective peroxisome proliferator activated receptor-α (PPAR-α) agonists.
Gangwal RP; Damre MV; Das NR; Sharma SS; Sangamwar AT
Bioorg Med Chem Lett; 2015 Jan; 25(2):270-5. PubMed ID: 25491112
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel PPARα/γ Dual Agonists by Virtual Screening of Specs Database.
Zhang J; Liu X; Wang SQ; Fu JW; Xu WR; Cheng XC; Wang RL
Comb Chem High Throughput Screen; 2016; 19(8):644-655. PubMed ID: 27316369
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulations.
Feng XY; Jia WQ; Liu X; Jing Z; Liu YY; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():178-189. PubMed ID: 30557816
[TBL] [Abstract][Full Text] [Related]
18. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening, molecular dynamics, density functional theory and quantitative structure activity relationship studies to design peroxisome proliferator-activated receptor-γ agonists as anti-diabetic drugs.
Ahmed S; Islam N; Shahinozzaman M; Fakayode SO; Afrin N; Halim MA
J Biomol Struct Dyn; 2021 Feb; 39(2):728-742. PubMed ID: 31916505
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone.
Wang XJ; Zhang J; Wang SQ; Xu WR; Cheng XC; Wang RL
Drug Des Devel Ther; 2014; 8():2255-62. PubMed ID: 25422585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]